Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$1.71
$0.01(0.80%)
At close: 4:00 PM EDT
$1.71
$0.01(0.80%)
Day’s Range― - ―
52-Week Range$0.80 - $2.24
Previous Close$1.26
Volume536.26K
Average Volume (3M)2.63M
Market Cap
$62.98M
Enterprise Value$72.05M
Total Cash (Recent Filing)$34.82M
Total Debt (Recent Filing)$877.00K
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 03, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume3,787,209
30 Day Avg. Volume2,626,140
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-774.77
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$7.33Price Target Upside328.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Covalent Chemistry PlatformThe proprietary covalent chemistry platform gives Biomea a defined discovery engine spanning oncology and metabolic disease targets. A reusable platform can support multiple development programs and create broader scientific optionality than relying on a single drug candidate, although clinical validation remains necessary.
Oral GLP-1 Development OpportunityBMF-650 addresses meaningful practical barriers in GLP-1 treatment, including administration simplicity, gastrointestinal tolerability and persistence. If clinical testing supports these attributes, the program could improve Biomea’s positioning in metabolic disease and broaden the value of its pipeline beyond oncology.
Improving Loss TrajectoryMaterially narrowing losses indicate improved cost control and a more disciplined operating trajectory, even though the company remains unprofitable. Continued expense management can extend the usefulness of available capital and preserve resources for clinical development while pipeline milestones are pursued.
Bears Say
No Revenue And Persistent UnprofitabilityWith no commercial revenue, Biomea currently lacks an operating income stream to fund research and clinical development. Persistent operating losses and negative gross profit mean financial progress depends on successful product development and eventual commercialization rather than an established earnings base.
Substantial Cash Burn And Financing DependencePersistent negative operating and free cash flow requires Biomea to obtain external financing until revenue generation or partnership funding materializes. This constrains strategic flexibility, makes development plans sensitive to funding access, and can dilute existing shareholders or force prioritization among programs.
Shrinking Equity Capital CushionThe sharp decline in equity reflects cumulative losses and leaves Biomea with a materially thinner capital cushion than in earlier periods. Low leverage reduces debt risk, but does not offset the reduced balance-sheet capacity to absorb setbacks or finance several clinical programs internally.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.80 and its highest was $2.24 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $62.98M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Nov 03, 2026 which is in 15 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Aug 05, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.223 by $0.103.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.21.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,483,850 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.223. Following the earnings report the stock price went down -0.794%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.33 (328.85% Upside)
$7.33 (328.85% Upside)
Blogger Sentiment
Bullish
BMEA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 53.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.40%
12-Months-Change
Fundamentals
Return on Equity
-171.19%
Trailing 12-Months
Asset Growth
-49.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biomea Fusion
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.33
▲(328.85% Upside)
Technical Analysis
Ownership Overview
3.71% Insiders
11.19% Mutual Funds
4.75% Other Institutional Investors
76.13% Public Companies and
Individual Investors